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Το ηλεκτρονικό τσιγάρο είναι μια εναλλακτική μορφή καπνίσματος, ένα προϊόν της 
σύγχρονης τεχνολογίας που αποτελείται από μια επαναφορτιζόμενη μπαταρία, τον 
ατμοποιητή και τα αναλώσιμα φίλτρα, σε μια συσκευή που μοιάζει με τα συμβατικά τσιγάρα. 
Η ευρεία κατανάλωση των ηλεκτρονικών τσιγάρων έχει εγείρει το ενδιαφέρον και την 
ανησυχία της ιατρικής κοινότητας διεθνώς, από τη στιγμή που δεν υπάρχει ικανός αριθμός 
τεκμηριωμένων ερευνών ως προς τις πιθανές παρενέργειες τους ή οφέλη τους. Η παρούσα 
μελέτη εξετάζει τις βραχυπρόθεσμες επιπτώσεις του ενεργητικού καπνίσματος συμβατικού 
και ηλεκτρονικού τσιγάρου σε ασθενείς με διαγνωσμένη Χρόνια Αποφρακτική 
Πνευμονοπάθεια (ΧΑΠ). Εξετάσθηκαν 16 εθελοντές (8 άνδρες, 8 γυναίκες, όλοι καπνιστές 
με >25p/y) που υποβλήθηκαν σε τρείς συνεδρίες: μια κατάσταση ελέγχου, μια κατάσταση 
ενεργητικού καπνίσματος συμβατικού τσιγάρου και μια κατάσταση ενεργητικού 
καπνίσματος ηλεκτρονικού τσιγάρου. Σπιρομετρικός έλεγχος πραγματοποιήθηκε ακριβώς 
μετά το κάπνισμα σε κάθε συνεδρία. Επίσης, δεδομένα οξυμετρίας και αερίων αίματος 
συλλέχθηκαν σε όλες τις συνεδρίες σε τρείς φάσεις (πριν το κάπνισμα, ακριβώς μετά το 
κάπνισμα, και μια ώρα μετά το κάπνισμα). Τα αποτελέσματα του σπιρομετρικού ελέγχου 
έδειξαν ότι τα συμβατικά τσιγάρα επηρεάζουν σημαντικά τη λειτουργία του αναπνευστικού, 
όπως φάνηκε από τις σημαντικές πτώσεις στο FEV1 και στο Δείκτη Tiffneau (p<0.05). 
Αντίθετα, τα ηλεκτρονικά τσιγάρα δεν άλλαξαν σημαντικά τα αποτελέσματα του 
σπιρομετρικού ελέγχου (p>0.05). Τα συμβατικά τσιγάρα επηρέασαν αρνητικά τα PaO2, 
PaCO2, HCO3, και την οξυμετρία (p<0.05). Αντίθετα, τα ηλεκτρονικά τσιγάρα δεν 
επηρέασαν σημαντικά τα αποτελέσματα των μετρήσεων αυτών (p>0.05). Με βάση τα 
παραπάνω, συμπεραίνεται ότι το κάπνισμα ηλεκτρονικού τσιγάρου δεν επιφέρει σημαντικές 
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βραχυπρόθεσμες μεταβολές στους δείκτες του σπιρομετρικού ελέγχου, οξυμετρίας και 
αερίων αίματος σε ασθενείς με διαγνωσμένη ΧΑΠ. 
 
Λέξεις-κλειδιά: ηλεκτρονικά τσιγάρα, κάπνισμα, ΧΑΠ, αναπνευστική λειτουργία, 
σπιρομέτρηση. 
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Electronic cigarette is an alternative mode of smoking, a product of modern technology that 
is consisted of a battery powered device that has a simulating role in vaporizing nicotine into 
inhalable vapour and filters in size and shape similar to conventional cigarette. Its growing 
popularity starts to alert the medical community worldwide from the moment that there are 
not sufficient, scientifically documented research results for their possible benefits or hazards 
on healthy population or among people with chronic diseases. In this randomized crossover 
trial we attempt to examine the acute effects of conventional and electronic cigarette smoking 
in 16 patients (8 male, 8 female, all active smokers >25p/y) with diagnosed Chronic 
Obstructive Pulmonary disease (COPD). They were examined in three sessions, a control 
condition, a conventional cigarette smoking condition and an electronic cigarette condition. 
Spirometry measurements were taken immediately after smoking in each condition. 
Moreover, oxygen saturation and arterial blood gases were measured before, immediately 
after smoking, and one hour after smoking in each condition. The results from spirometry 
demonstrated that tobacco cigarettes generated a significant detrimental effect on lung 
function, evident by the reduction in FEV1 and Tiffneau Index (p<0.05). In contrast, e-
cigarettes did not produce any statistically significant effects on spirometry results (p>0.05). 
In terms of arterial blood gas analysis, PaO2, PaCO2, HCO3, and oxygen saturation were 
unfavourably affected by tobacco cigarettes (p<0.05). In contrast, e-cigarettes did not produce 
any statistically significant effects on the results of arterial blood gases (p>0.05). Based on 
the results of this study, it is concluded that acute e-cigarette smoking does not affect lung 
function (as assessed by spirometry) and arterial blood gases in COPD patients. In contrast, 
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acute tobacco cigarette smoking undermines lung function and arterial blood gases in these 
patients. 
Keywords: e-cigarettes, smoking, tobacco, COPD, lung function, spirometry.
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Cigarette smoking began centuries ago and currently ~20% of the world’s adult population 
smokes cigarettes. Smokers consumed nearly 5.9 trillion cigarettes in 2009, representing a 
13% increase in consumption compared to 1999 (WHO, 2008b). In terms of cigarette 
consumption, Greece is the first country among the European countries and third in the 
world, in both sexes, while it was 6th in the consumption of tobacco worldwide in 2008 
(WHO, 2008b). The increased prevalence of smoking is ever increasing, despite its 
advertised unfavourable health effects. The World Health Organization states that smoking 
kills one person every six and half seconds somewhere in the world; this is either because of 
direct smoking or passive smoking (WHO, 2012). According to recent data, smoking is 
responsible for killing one person out of five people who suffer from cancer or around 1.4 
million death cases around the world every year (WHO, 2012). 
Given the economic and public health concerns for smoking, smoking cessation is a 
major concern in order to reduce morbidity and mortality. Behavioural modification, nicotine 
replacement products (e.g. patches, gums etc), medications (bupropion, varenicline) and 
lately electronic cigarettes are the means that are usually used. The electronic cigarette (e-
cigarette) was introduced in China in 2004, patented by a pharmacist, and then it was 
widespread worldwide. Its popularity has increased over the last years based on the 
advertised claim that it can be used as an effective means of reducing or stopping smoking, a 
smoke-free method in public places, and also as a cheaper way of smoking (Ayers et al., 
2011). However, only limited data are available on e-cigarettes. On their website, the U.S. 
FDA states that “E-cigarettes may contain ingredients that are known to be toxic to humans, 
and may contain other ingredients that may not be safe”. They also suggest that because their 
manufacturers are not required to submit clinical study data to them, the public has no way of 
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knowing “ whether e-cigarettes are safe for their intended use, what types or concentrations 
of potentially harmful chemicals are found in these products, or how much nicotine they are 
inhaling when they use these products.” The FDA is also concerned that the marketing effects 
of e-cigarettes may increase addiction to nicotine, especially in young people, encouraging 
them to experiment with real tobacco products. Similar statements have been made from 
WHO (WHO study group on tobacco product regulation, 2009). 
Lung function tests on patients with chronic obstructive pulmonary disease (COPD) 
using e-cigarettes lack at this moment. At present, most clinicians are sceptical about their 
use and they don’t recommend e-cigarettes as a means of stopping cigarette smoking. Active 
smoking is a well-known process that gradually produces a deterioration of lung function 
(Flouris & Koutedakis 2011) but there is no such evidence concerning the e-cigarette. No 
matter if e-cigarette is a pioneer product, there are limited data concerning its efficiency but 
most important, of their safety (Flouris & Oikonomou, 2010). 
 
1.1. Aim of the study 
In this study our aim was to analyse the effects of conventional and e-cigarette consumption 
based on basic parameters such as spirometry and arterial blood gas analysis. For this reason 
we recruited COPD patients with different grade of severity of disease. 
The expected impact of this work is to report if there is any clinical significance of 
our results, in order to help the healthcare community to provide recommendations to COPD 
patients regarding the use of e-cigarettes. 
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2. LITERATURE REVIEW 
2.1. History of tobacco smoking 
Tobacco, a native plant of Americas was first discovered 18.000 years ago when migrant 
Asiatic people crossed the Bering Strait and spread across the continents known today as the 
Americas where tobacco is native (Gilman & Xun, 2004). Tobacco is related to garden 
vegetables belonging to the family plant of Solanaceae; the genus Nicotiana Contaius with 
about 100 species, only two of which have been extensively cultivated Nicotiana Tabacum 
(being the predominant mostly used crop tobacco) and Nicotiana Rustica. 
Tobacco use dates back as early as 5.000 – 3.000 BC, used by Indians of North 
America in the region Andes (Gilman & Xun, 2004). It was used for ritual ceremonies and 
smoke was believed to carry the prayers to gods. Beside the ritual practices, it was believed to 
be a cure-all, e.g. to dress wounds and as an analgesic. Tobacco chewing was probably the 
first way that tobacco was consumed. In that way it was believed to relieve toothache. 
Anthropologists speculated that snuffling – taking powdered tobacco through the nose – 
probably predated smoking. Snuffing Y shaped tubes are among the earliest tobacco artefacts 
discovered in the Americas (Gilman & Xun, 2004). 
The name tobacco was originally applied to the plant in error. In fact this term 
referred to the cane pipe, called tobacco or tavaco, with two branches for the nostrils, which 
has been used by the native Americas for sniffing tobacco smoke (Gately, 2001). Smoking 
tobacco by the natives was made able by wrapping leaf in corn husk to produce the 
forerunner of cigarette. Soon after the first trip of Colombus, it didn’t take long for tobacco to 
be criticized on a Christianity basis. Hispaniola’s military governor, Gonzalo Fernadez de 
Oviedo, wrote of the indigenous people’s evil customs emphasizing on “one that is especially 
harmful: the ingestion of a certain kind of smoke, they call tobacco, in order to produce a 
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state of stupor”. He concluded that its use has a harmful effect appears to be spiritual, as the 
productive soul is deadened by the product’s intoxicating quality (Gately, 2001). 
European Christians soon observed tobacco in native ritual that looked absolutely 
satanic “an active tool of the Antichrist” as well as in individual instances by shamans who 
seemed to use it as a “medium for communication with the devil himself” (Gately, 2001). 
Early European practitioners noticed its power and it’s addictive properties. Colombus is 
quoted having said “it was not within their power to refrain” from smoking having become 
accustomed to it (Parker & Pope, 2001). 
Through the native Indians and based on their assumption of its therapeutic effect, as 
an analgesic and local antiseptic (Gately, 2001), the first seeds were taken to Europe (Spain) 
in 1559 by Hernadez  Bancolo of Toledo. Ambassador of France in Portugal Jean Nicot de 
Villemain (1530-1600) introduced its use in France, as a wonder drug to the French court, 
and soon by mid 1600 tobacco had been introduced to every major civilized culture around 
the world through major trade routes to ports and markets (Gately, 2001). 
Tobacco got a boost in Europe for its reputed medicinal properties as taught by Jean 
Nicot who had heard stories of tobacco’s curative power and sent seeds to Catherine de 
Medici (Gately, 2001). Through most known as an appetite suppressant, physicians went so 
far as to prescribe smoking to prevent the plague (Gately, 2001). Meanwhile, a pamphlet 
entitled Joyful News of our Newe Founde Worlde published by Spanish doctor Nicolas 
Monardes praised the tobacco use while underlying that someone should be “careful to 
refute…the charge that tobacco was the Devil’s herb”. The pamphlet generated a wave of 
interest in tobacco across Europe as it was translated into Latin, English, French and Italian 
(Gately, 2001). Gradually the new habit of smoking tobacco started to be affordable not only 
by the rich people and became available to the majority of people in Europe (Gilman & Xun, 
2004). 
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Smoking for pleasure received its greatest endorsement from Sir Walter Raleigh who 
was “a favourite of the queen of England being something of a trendsetter in the fashion – 
conscious circles of Elizabethan London” (Parker & Pope, 2001). The popularity of tobacco 
in England prompted the English colonial tobacco industry, which was boosted by John 
Rolfe’s move in Jamestown to acquire the finer Nicotiana Tobaccum (to replace the more 
bitter rustica) allowing the first shipment of tobacco to England by 1613 (Parker & Pope, 
2001). 
The English developed a preference for the pipe, based on their interactions with 
North American Indians, while the Spanish preferred the cigar a closer relative to the 
smoking encountered on their exploration in the New World (Parker & Pope, 2001). Sniff 
was popular in the French court and it soon spread into the country as tobacco prices came 
down; again also thanks to big tobacco ventures in the New World. Americans themselves 
developed a strong preference for chewing tobacco, a habit disdained by Continental visitors 
but one that remained popular into the 19th century (Parker & Pope, 2001). 
Around the world, sailors and global trade disseminated tobacco and smoking habits. 
Cultivation became widespread not only in America, but across the African and Asian 
continents as well. Its use not only in the Ottoman Empire but also in India, Africa and 
Central Asia was widespread with great speed (Parker & Pope, 2001). Even Japan became 
familiar with the new habit around 1540. Tobacco was instantly popular though, as 
elsewhere, first in the higher status of Japanese society, where it was favoured by samurai 
knights who created “ornate silver tobacco pipes” and formed smoking clubs in which to 
gather and share in the pleasure of tobacco (Parker & Pope, 2001). 
Early in the 19th century, while much of Europe was under Napoleonic influence, the 
French army occupying Spain came into contact with popular Spanish tobacco products 
including the cigaritos, the Spanish diminiture of cigar which gradually became so popular 
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becoming cigarette in French, now “the most commonly used French word in the planet” 
(Gately, 2001). Beside advertisement, two key innovations helped its widespread use during 
the 19th century. First, in 1839 after an accident with fire near a tobacco storage house it was 
proven that dried tobacco was much milder and more flavourful (Parker & Pope, 2001). The 
second innovation was when Virginian James Bonsack patented a machine to manufacture 
cigarettes and Bull Durcham took a gamble on the machine as tobacco’s future. When the 
machine begun producing 200 cigarettes a minute – as many as 40 human employees rolling 
by hand – the future of the cigarette was, indeed, solidified (Gately, 2001). 
Due to the widespread popularity of smoking among the European societies and even 
worldwide, soon appeared legislations against it (Lader & Henningfield, 1985). One of the 
earliest bans was a 1575 regulation by the Mexican church which forbade smoking in 
churches in Mexico and at the Spanish colonies in the Caribbean (Lader & Henningfield, 
1985). In England, in 1604 king James I of England regulated the Counterblaste to Tobacco 
that had the effect of taxes on tobacco trade (Lader & Malcolm 1985). At East, Sultan Murad 
IV prohibited smoking in the entire Ottoman Empire in 1633. Pope Urban VII and VIII 
prohibited smoking in the church at 1590 and 1633 respectively (Lader & Malcolm 1985). In 
central Europe, banning of smoking appeared first in the Bavarian region of Germany and 
certain parts of Austria in the late 17th century (Lader & Malcolm 1985). 
The first attempt in modern history to restrict smoking was held by the Nazi regime in 
any public service of the country. Under the instructions of Karl Astel’s Institute for Tobacco 
Hazards Research, this ban was announced in 1941 under orders from Adolf Hitler (Proctor, 
2001). Major anti-tobacco campaigns were widely broadcasted by the Nazis until the fall of 
the regime (Proctor, 1996). After the 1950’s, evidence of the correlation of smoking with 
several diseases (especially lung cancer) started accumulating. Individuals started to sue the 
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companies by the mid 1950’s (MSA Agreement). The accusations were mostly about 
negligent manufacture (Proctor, 1996). 
Different policies were enforced around the world in the latter part of the 20th 
century. Ban of smoking in USA started from 1975, in the US state of Minnesota, prohibiting 
smoking in public spaces. Gradually other states including Colorado and California followed 
Minnesota’s example ((King & Siegel, 2001; www.no-smoke.org). In November 1988, the 
four largest United States tobacco companies and the attorney general of 46 states signed the 
Tobacco Master Settlement Agreement. The states settled with the companies for recovery of 
their tobacco-related health care costs and also exempted the companies from private tort 
liability regarding harm caused by tobacco use. Furthermore, this agreement ensured that the 
companies will invest large amounts of funds for advertising the health risks of smoking, that 
they will collaborate towards reducing smoking initiation by youth, and that they will fund 
the creation of an antismoking institute (King & Siegel, 2001). 
In Peru it is illegal to smoke in any public enclosed places and in any public transport 
vehicles (law 25357) since 1993. By December 2004 there was a smoking ban in schools and 
workplaces in New Zealand (Smoke free law in New Zealand. moh.govt.nz). In 2004 Ireland 
became the first country in Europe to ban smoking in all workplaces, including bars and 
restaurants. By 2007, smoking was banned in all public places in most European countries 
and Turkey took such measures in 2008.  
Despite these measures as well as the well-known dangers of smoking, tobacco 
consumption is steady rising (WHO, 2008b). Nearly 20% of the world’s adult population 
smokes cigarettes. Smokers consumed nearly 5.9 trillion cigarettes in 2009, representing a 
13% increase in consumption during the past decade (WHO, 2008b; www.tobaccoatlas.org). 
Greece is the first country among the European countries and third in the whole world, in 
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both sexes, while it was 6th in the consumption of tobacco worldwide in 2008 (WHO, 
2008b). 
 
2.2. Health hazards of cigarette smoking 
The Journal of the American Medical Association published the landmark 1950 studies of 
Ernest Wynder (Wynder & Graham, 1950) and Martin Levin (Levin et al., 1950) that showed 
a statistical correlation between incidents of lung cancer and heavy smokers. The British 
Medical Journal followed (Doll & Hill, 1950), and the two journals became homes to many 
studies to be released over the following decades demonstrating statistical reason of concern. 
Negative health effects had long been suspected to be related to some part of the process of 
smoking, but the deep inhalation of smoke by cigarette smokers was proven to be especially 
harmful, and such studies became the catalyst for countless additional examinations into the 
ancient pleasure of tobacco. 
Cigarette consumption historically has been highest in high income countries, but 
because of targeted marketing, increased social acceptability, continued economic 
development, and population increases, consumption is expected to increase in low and 
middle income countries (WHO, 2012). Cigarette consumption in Western Europe dropped 
by 26% between 1990 and 2009 but increased in Middle East and Africa by 57% during the 
same period. This change has occurred as people in high-income countries increasingly 
understand the dangers of smoking and governments continue to implement tobacco control 
policy and legislation. Globally the increase in cigarette consumption in low- and middle-
income countries is significantly enough to offset the decrease in high-income countries 
(WHO, 2012). Another factor related to global smoking prevalence is the population growth. 
China is a typical example. Chinese men smoke a third of the world’s cigarettes. As Chinese 
women smokers also increase in numbers, global consumption of cigarettes will skyrocket 
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and the country’s economy and healthcare system will be overwhelmed, as this has happened 
in other countries in the past (WHO, 2012). 
Cigarette smoking is the number one cause of preventable disease and death 
worldwide (WHO, 2012; www.lung.org). Smoking harms nearly every organ in the body, 
and it is a main cause of lung cancer and COPD. It is also a cause of coronary heart disease, 
stroke and a host of other cancers and diseases (US Department of Health and Human 
Services, 2004), as indicated in figure 1. There are some interesting facts concerning 
smoking. Cigarette smoke contains over 4.800 chemicals, 69 which are known to cause 
cancer. Smoking is directly responsible for approximately 90% of lung cancer deaths and 
approximately 80-90% of chronic obstructive pulmonary disease (COPD; emphysema and 
chronic bronchitis) deaths (Centers for Disease Control and Prevention, 2004). Among 
current smokers, chronic lung disease accounts for 73% of smoking-related conditions 
(Centers for Disease Control and Prevention, 2003). 
 
Figure 1. Health effects of tobacco smoking. 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:04:04 EET - 137.108.70.7
19 
 
2.3. Smoking Rates among Adults & Youth 
In 2009, an estimated 46.6 million or 20.6% of adults (aged 18+) were current smokers 
(Centers for Disease Control and Prevention, 2009). Men tend to smoke more than women, 
but their difference starts to decrease. Smoking in pregnancy accounts for an estimated 20-
30% of low birth weight babies, up to 14% of preterm deliveries, and 10% of all infant 
deaths. Even apparently healthy, full term babies of smokers have been found to be born with 
narrowed airways and reduced lung function (US Department of Health and Human Services, 
2001). Moreover, smoking is a major cause of premature death worldwide (WHO, 2011; Jha, 
2009). 
Passive smoking refers to the smoke that non-smokers are breathing in from the 
smokers. People who spend time around smokers are breathing in the smoke either from the 
burning end of the active smoker’s cigarette or the smoke exhaled by the active smoker. This 
is called involuntary or secondary smoking. Exposure to second hand smoke can lead to very 
serious health problems, such as respiratory diseases, heart disease, lung cancer and even 
dementia (Chen et al., 2012). Passive smoking is considered a preventable cause of death that 
has killed thousands of people exposed to cigarette smoke in homes, workplaces and/ or in 
public (Chen et al., 2012). 
When a cigarette is smoked about half of the smoke is inhaled/exhaled (mainstream 
smoke) by the smoker and the other half floats around in the air (sidestream smoke). The 
combination of mainstream and sidestream smoke makes up second hand smoke also known 
as environmental tobacco smoke. When nonsmokers are exposed to second hand smoke, they 
inhale many of the same cancer-causing chemicals that smokers inhale. 
Both sidestream and mainstream smoke are dangerous to nonsmokers. For example, 
because sidestream smoke is generated at lower temperatures and under different conditions 
than mainstream smoke, it contains higher concentrations of many of the toxins found in 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:04:04 EET - 137.108.70.7
20 
 
cigarette smoke. There is no risk free level of exposure to second hand smoke; even small 
amounts of second hand smoke exposure can be harmful to people’s health. The World 
Health Organization states that smoking kills one person every six and half seconds 
somewhere in the world; this is either because of direct smoking or passive smoking (WHO, 
2012). According to recent data, smoking is responsible for killing one person out of five 
people who suffer from cancer or around 1.4 million death cases around the world every year 
(WHO, 2012). 
 
2.4. Active smoking and lung function 
Damage to the respiratory system from cigarette smoking is slow, progressive, and deadly. A 
healthy respiratory system is continuously cleansed. The mucus produced by the respiratory 
tubules traps dirt and disease-causing organisms, which cilia sweep toward the mouth, where 
it can be eliminated. Smoking greatly impairs this housekeeping. With the very first 
inhalation of smoke, the beating of the cilia slows. With time, the cilia become paralyzed and, 
eventually, disappear altogether (U.S Department of Health and Human Services, 2010). The 
loss of cilia leads to the development of smoker's cough. The cilia no longer effectively 
remove mucus, so the individual must cough it up. To make matters worse, excess mucus is 
produced and accumulates, clogging the air passageways. Pathogenic organisms that are 
normally removed now have easier access to the respiratory surfaces and the resulting lung 
congestion favours their growth (U.S Department of Health and Human Services, 2010). 
This above-mentioned process causes the development of COPD, an obstructive lung 
disease in which chronic incompletely reversible airflow limit exists (U.S Department of 
Health and Human Services, 2010). This airflow limitation is due to breakdown of lung tissue 
(known as pulmonary emphysema) and small airway disease (known as obstructive 
bronchiolitis or bronchitis depending the size of the small airways). It develops secondary to 
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a more pronounced and chronic inflammatory response to inhaled irritants. The most 
important processes causing lung damage is the oxidative stress produced by the high 
concentrations of free radicals in tobacco smoke and cytokine release due to inflammation as 
the body responds to irritant particles such as tobacco smoke in the airway (Flouris et al., 
2010). Both of them lead to impaired activity of antiprotease enzymes such as alpha 1-
antitrypsin, allowing protease enzymes to damage the lung (Flouris et al., 2010). 
Chronic inflammation plays a major role in COPD pathophysiology. Smoking and 
other airway irritants cause neutrophils, T-lymphocytes, and other inflammatory cells to 
accumulate in the airways. Once activated, they trigger an inflammatory response in which an 
influx of molecules, known as inflammatory mediators, navigates to the site in an attempt to 
destroy and remove inhaled foreign debris (Flouris et al., 2010). 
Under normal circumstances, the inflammatory response is useful and leads to 
healing. In fact, without it, the body would never recover from injury. In COPD, repeated 
exposure to airway irritants perpetuates an ongoing inflammatory response that never seems 
to cease. Over time, this process causes structural and physiological lung changes that get 
progressively worse. As inflammation continues, the airways constrict, becoming excessively 
narrow and swollen. This leads to excess mucus production and poorly functioning cilia, a 
combination that makes airway clearance especially difficult. When people with COPD can't 
clear their secretions, they develop the hallmark symptoms of COPD, including a chronic, 
productive cough, wheezing and dyspnoea. Finally, the build-up of mucus attracts a host of 
bacteria that thrive and multiply in the warm, moist environment of the airway and lungs. The 
end result is further inflammation and bacterial lung infection, a common cause of COPD 
exacerbation (U.S Department of Health and Human Services, 2010). 
Airflow obstruction is defined as a reduced post-bronchodilator FEV1/FVC ratio 
(where FEV1 is forced expiratory volume in 1 second and FVC is forced vital capacity), such 
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that FEV1/FVC is less than 0.7 (U.S Department of Health and Human Services, 2010). If 
FEV1 is 80% or more of predicted normal, a diagnosis of COPD should only be made in the 
presence of respiratory symptoms, e.g. breathlessness or cough. Patients with COPD may 
present with loss of lung function beyond normal age-related decreases. Clinical disease 
develops fairly late in the disease course, after lung function drops below threshold values. 
After 25 years of age, a nonsmoking adult’s FEV1 decreases by an average of 20 to 
40 ml per year (figure 2). In some smokers, FEV1 decreases by two to five times this amount, 
making them particularly susceptible to COPD (Barnes, 2000). Smoking cessation may cause 
slight initial improvement in FEV1 (approximately 50 mL in the first year). More 
importantly, smoking cessation can give a former smoker the same average ongoing loss of 
lung function as a never-smoker. 
 
Figure 2. The progressive loss of lung function in a variety of settings. 
 
Patients with COPD usually have a smoking history of at least 20 pack-years. 
Wheezing and dyspnea on exertion generally occur when the FEV1 is less than 50% of the 
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predicted value, and significant physical disability usually occurs when the FEV1 is less than 
35-40% of the predicted value (Doherty, 2002; Mannino 2002). Patients who started smoking 
in their 20s and have already sustained appreciable FEV1 loss by their 40s are likely to 
develop significant COPD if they continue to smoke. Those in their mid-40s who have 
normal FEV1 values, however, probably will not develop symptomatic disease. 
The GOLD guidelines (Global Initiative for Obstructive Lung Disease, 2005; 
American Thoracic Society, 1995) characterize the severity of COPD according to clinical 
and spirometric measures. Key spirometric measures may be obtained with a portable office 
spirometer and should include FVC and FEV1. Patients with COPD typically present with 
obstructive airflow. According to the GOLD criteria, a FEV1/FVC ratio of less than 70% in a 
patient with a post bronchodilator FEV1 of less than 80% of the predicted value is diagnostic 
for COPD (Global Initiative for Obstructive Lung Disease, 2005; American Thoracic Society, 
1995). Severity is further stratified based on symptoms and FEV1 values. A patient with 
severe disease has a FEV1 of less than 50% of the predicted value; values below 30% of the 
predicted value represent very severe disease (Global Initiative for Obstructive Lung Disease, 
2005; American Thoracic Society, 1995). Although some experts have proposed periodic 
FEV1 testing for high-risk patients older than 45 years to facilitate risk factor reduction 
counselling, no evidence exists to support this recommendation (Global Initiative for 
Obstructive Lung Disease, 2005; American Thoracic Society, 1995). 
 
2.5. The introduction of the electronic cigarette 
As discussed above, smoking has been an economic and public health issue for many years. 
Thus, smoking cessation was and certainly is a major issue in order to reduce morbidity and 
mortality. Behavioural modification, nicotine replacement products (e.g. patches, gums etc), 
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medications (bupropion, varenicline) and lately electronic cigarettes are the means that are 
usually used. 
The official terminology used to describe the electronic cigarettes is electronic 
nicotine delivery systems (WHO, 2010). It was introduced in China in 2004, patented from a 
pharmacist, and then it was widespread worldwide. Its popularity has increased over the last 
years based on the facts that it can be used as an effective means of reducing or stopping 
smoking, a smoke-free method in public places, and also as a cheaper way of smoking (Ayers 
et al., 2011). Electronic cigarettes (e-cigarettes) can be purchased on the internet or through 
retail venues. Although manual systems also exist, the most popular form is the automatic 
type. Different brands are available that have different concentration of nicotine, as well as 
flavours. Most e-cigarette devices are composed of four parts (figure 3): 1) the mouthpiece 
(or cartridge), 2) the atomizer chamber and heating coil, 3) the battery, and 4) the LED light 
cover. 
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The mouthpiece is a disposable and opens at each end, contains the liquid that will be 
vaporized. This liquid is made of nicotine, propylene glycol, flavourings and chemical 
substances (e.g. rimonabant). This liquid is vaporized by heating, which is inhaled. Below the 
cartridge is a lithium ion battery and a chip controller with an operating mode sensor and a 
LED sensor that lights up with a puff. Every e-cigarette includes a rechargeable battery, a 
battery charger, and a choice of flavour. The cost of the device is about 50 euros or above and 
each refill costs about 7 euros. Automatic style requires only puffing or taking a drag to 
activate the atomizer. The e-liquid in the filter heats up to produce the vapour. The 
concentration of nicotine varies from 0 to 40 mg. 
The original intent of an e-cigarette was to imitate the nicotine delivery system of a 
conventional cigarette without the harmful effects of tobacco smoke combustion (Kuschner et 
al., 2011). The e-cigarette is advertised to look and taste similar to a real cigarette and to give 
a nicotine fix. When the button is clicked on the e-cigarette, the liquid nicotine, flavours, and 
chemicals present in the plastic tube heat up and an atomizer (aerosol) turns into a vapour that 
is puffed or inhaled and enters into the airway, which is rapidly absorbed into the systemic 
circulation, giving a dose of nicotine in the brain (http://uspharmacist.com/). 
A dispute has been raised over the safety of the chemical components of the e-
cigarettes. Data are available about the effects of nicotine so the major interest was focused 
on the effect of propylene glycol. Also called 1,2 propanediol, it is an organic compound with 
formula C3H8O2, a colorless, nearly odorless, clear, viscous liquid. It is found in personal 
care products that act as a penetration enhancer that keeps products from melting in heat and 
or freezing when it is cold. It is found in items such as shampoo, soap, toothpaste, deodorant, 
nail polish. According to several sources, it has been linked to cancer, 
developmental/reproductive issues, allergy and immunotoxicity, neurotoxicity, endocrine 
disruption and multiorgan toxicity (Choi & Schmidbauer, 2010; www.evg.org). 
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In the body under conditions of normal low exposure, propylene glycol is quickly 
metabolized and eliminated. Its metabolic pathway is comparable to that of sugar; it is rapidly 
converted to lactic acid which is discarded by the body via the urine. Several countries and 
official institutions have investigated these issues. In the U.S., FDA analysis over nicotine 
and propylene glycol has showed that PG levels were “generally recognized as safe” 
provided that their concentration was less than 2% (accessdata.fda.gov). Nicotine release by 
the e-cigarettes in some specimens was not uniformly released and also the percentage of 
concentration of nicotine in its liquid was not accurate. Other metabolites such as 
acetaldehyde, acrolein, polycyclic hydrocarbons and even diethylene glycol were accused of 
being harmful in the use of e-cigarettes (Westenberger, 2009). 
An important issue to be concerned is the rapid growth of the e-cigarette industry and 
their enormous profits (Pauly & Li, 2007). Smart advertisement campaigns have played a key 
role to this growth. This industry only in US is expected to double its revenue over last year 
reaching to a profit of 1 billion dollars, burning away the gap with the traditional cigarette 
industry (forbes.com). E-cigarette companies take advantage of the lack of law and 
regulations, as in US that it’s free for them to advertise their products on television and give 
out free samples. Even though there is not enough evidence for their efficiency and safety 
their use keeps rising (Flouris & Oikonomou, 2010). 
E-cigarettes were proposed as a replacement mean or a cessation aid for quitting 
traditional smoking. As that there was not enough scientific evidence about their safety, 
WHO asked the manufacturers not to promote them as a therapeutic aid (WHO study group 
on tobacco product regulation, 2009). In many countries the e-cigarette lacks important 
regulatory factors, such as health warnings, proper labeling, clear instructions on how to use 
them, and safe disposal methods (Bullen et al., 2010). There is a big controversy among 
different studies worldwide about their advantages and disadvantages. During an online 
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survey conducted in 2010, researchers polled visitors of websites and discussion forums 
dedicated to the use of e-cigarette and smoking cessation. Of the 3.587 participants, 70% 
were former smokers, 61% were men, and the median age was 41 years. On average, 
participants used the e-cigarette for approximately 3 months, drew 120 puffs/day, and used 5 
cartridges/day. Almost all of them used cartridges that contained nicotine. A total of 96% 
stated that the e-cigarette helped them quit smoking, while 92% said that it made them smoke 
less. A majority of the participants said the e-cigarette helped them fight cravings, cope with 
withdrawal symptoms, and avoid relapsing on cigarettes (copd.about.com). In another case 
study series, the e-cigarette was found to help three study participants who all had a 
documented history of repeated failed attempts at smoking cessation, using professional 
smoking cessation assistance methods - quit smoking and remain abstinent for at least 6 
months (Caponetto et al, 2011). 
Limited data are available on e-cigarettes thus making official organizations being 
aware of their possible harms. On their website, the FDA states that “E-cigarettes may 
contain ingredients that are known to be toxic to humans, and may contain other ingredients 
that may not be safe”. They also suggest that because their manufacturers are not required to 
submit clinical study data to them, the public has no way of knowing “ whether e-cigarettes 
are safe for their intended use, what types or concentrations of potentially harmful chemicals 
are found in these products, or how much nicotine they are inhaling when they use these 
products.” The FDA is also concerned that the marketing effects of e-cigarettes may increase 
addiction to nicotine, especially in young people, encouraging them to experiment with real 
tobacco products. Similar statements have been made from WHO (WHO study group on 
tobacco product regulation, 2009). 
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A total number of 16 volunteers with diagnosed COPD and ≥25 pack/years participated: 8 
males; 8 females; age: 65.9±9.4 years; pack years: 65.1±28.2; Fagerstrom scale: 7.5±1.6. 
Written consent was obtained by all volunteers (see Supplement). No alteration of therapy 
was made and no change of usual smoking habits. None of the participants used e-cigarettes 
in the past. 
 
3.2. Experimental design 
The study was conducted according to the principles expressed in the Declaration of Helsinki 
and was approved by the University of Thessaly Ethics Review Board (see Supplement) and 
the 3rd Pulmonary clinic of General Hospital Sotiria, Athens. Volunteers were examined 
during three conditions within a time interval of 10 days: a conventional cigarette smoking 
condition (TOB), an electronic cigarette condition (eCIG), and a control condition (CON). 
Prior to the start of each condition, participants were asked to abstain from active and passive 
smoking for at least 12 hours. The subjects’ medical history and smoking habits were 
recorded during their first visit. During the TOB condition, every volunteer was given half an 
hour in order to smoke 2 cigarettes of their favourite brand (puffs: 23.8±4.0). In the eCIG 
condition, volunteers were asked to draw a predetermined number of puffs using an e-
cigarette (puffs: 6.7±3.0). During the CON condition, all individuals were asked to pretend 
that they smoke an unlit cigarette of their favourite brand (puffs: 23.8±4.0). Spirometry 
measurements were taken immediately after smoking in each condition. Moreover, oxygen 
saturation and arterial blood gases were measured before, immediately after smoking, and 
one hour after smoking in each condition. 
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The e-cigarette used during the eCIG condition was the model Giant (Nobacco GP, 
Greece). Each device was fully charged before the visit and new cartridges were obtained. 
The e-cigarette liquid used (Nobacco USA, MIX, Nobacco G.P, Greece) had tobacco flavour 
and the percentage of nicotine contained was 11 mg/ml, matching the average concentration 
of conventional cigarettes (which usually range between 0-35 mg/ml). 
The total number of puffs drawn by an e-cigarette result in significantly lower 
percentage of nicotine absorption compared to that generated by the same number of puffs 
from a conventional cigarette (Eissenberg, 2010; Vansickel, et. al; 2010). On this basis we 
modified the number of puffs for every volunteer during the eCIG condition based on: 1) the 
tobacco cigarette to e-cigarette absorption ratio, 2) the content of nicotine on their 
conventional cigarette, 3) the nicotine concentration of e-cigarette liquid and 4) the number of 
puffs required to consume 1 ml of e-cigarette liquid. Based on the above facts, the e-cigarette 
puffs equivalent to that of one tobacco cigarette was calculated based on the equation: 
  e-cigarette puffs = (TOBnic ×1,5×50) /eCIG NIC 
where TOBnic is the tobacco cigarette content (in mg), 1,5 is the average tobacco cigarette / 
e-cigarette nicotine absorption ratio, 50 is the average number of puffs required to consume 1 
ml of liquid, and eCIG NIC is the e-cigarette liquid nicotine content (in mg/ml). The result in 
each case was multiplied by 2 since that was the number of conventional cigarettes smoked 
during the TOB condition. The above methodology has been recently published by our group 
(Flouris et al., 2013). 
 
3.3. Spirometry 
Spirometry measurements were taken immediately after smoking in each condition. It was 
done by the same investigator in the 3rd Pulmonary clinic of General Hospital Sotiria, Athens 
according to the American Thoracic Society recommendations (American Thoracic Society 
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1995) using a portable Spirometer (Spirolab II). The parameters that were taken under 
consideration were: forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1), 
Tiffneau Index (FEV1/FVC), peak expiratory flow, as well as forced expiratory flow in the 
25%, 50%, and 75% of FVC.  
 
3.4. Arterial blood gases 
Arterial blood gases [i.e., partial pressure of oxygen in arterial blood (PaO2, in mmHg), 
partial pressure of carbon dioxide in arterial blood (PaCO2, in mmHg), pH, and bicarbonate 
(HCO3, in mEq/L) were measured before, immediately after smoking, and one hour after 
smoking in each condition. The measurements were taken from brachial artery and the 
analysis was made immediately. The procedure took place in 3
rd
 Pulmonary Clinic of General 
Hospital Sotiria, Athens in its examination room after the consent of every patient. Each 
patient was informed about the procedure and all hygiene and safety regulations were taken 
in advance. Special attention was given from the moment that this is an interventional 
procedure, to be made by an experienced physician using a syringe of 30 G or 31 G. 
3.5. Blood oxygenation 
Arterial oxygen saturation was measured before, immediately after smoking, and one hour 
after smoking in each condition. The procedure took place in 3
rd
 Pulmonary Clinic of General 
Hospital Sotiria, Athens in its examination room after the consent of every patient. For the 
oximetry a Nonin portable oxymeter was used, placed at the index finger of each patient at 
the time intervals mentioned above. As a non interventional procedure it was easily accepted 




Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:04:04 EET - 137.108.70.7
31 
 
3.5. Statistical Analysis 
Friedman tests followed by post hoc Wilcoxon signed-rank tests were used to assess changes 
between conditions for the spirometry data (i.e., TOB, eCIG, and CON). These analyses were 
also used to assess changes over time (i.e., prior to, immediately after, and one hour after 
smoking) in each condition. The accepted level of significance was P≤0.05. 
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The results for FVC are illustrated in figure 4. The Friedman test demonstrated a significant 
effect of condition (i.e., TOB, eCIG, and CON) on FVC (p=0.02). Post hoc Wilcoxon signed-
rank tests revealed a significant difference between TOB and CON (p=0.03). The results for 
FEV1 are illustrated in figure 5. The Friedman test demonstrated a significant effect of 
condition on FEV1 (p<0.001). Post hoc Wilcoxon signed-rank tests revealed significant 
differences between TOB and eCIG (p<0.001) and between TOB and CON (p=0.001). 
Results for the Tiffneau Index are illustrated in figure 6. The Friedman test demonstrated a 
significant effect of condition on the Tiffneau Index (p=0.02). Post hoc Wilcoxon signed-
rank tests revealed significant differences between TOB and eCIG (p=0.02) and between 
TOB and CON (p=0.004). The Friedman tests for PEF (figure 7), FEF25 (figure 8), FEF50 
(figure 9), and FEF75 (figure 10), haematocrit (figure 11), as well as haemoglobin (figure 12) 
did not reveal any statistically significant effects of condition (p>0.05). 
 
Figure 4. The forced vital capacity (FVC) during the conventional cigarette (TOB), the 
electronic cigarette (eCIG), and the control (CON) conditions. 
 
Institutional Repository - Library & Information Centre - University of Thessaly




Figure 5. The forced expiratory volume in 1 second (FEV1) during the conventional cigarette 




Figure 6. The Tiffneau Index (FEV1/FVC) during the conventional cigarette (TOB), the 
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Figure 7. The results for peak expiratory flow (PEF) during the conventional cigarette 





Figure 8. The results for the forced expiratory flow in the 25% of the forced vital capacity 
(FEF25) during the conventional cigarette (TOB), the electronic cigarette (eCIG), and the 
control (CON) conditions. 
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Figure 9. The results for the forced expiratory flow in the 50% of the forced vital capacity 
(FEF50) during the conventional cigarette (TOB), the electronic cigarette (eCIG), and the 





Figure 10. The results for the forced expiratory flow in the 75% of the forced vital capacity 
(FEF75) during the conventional cigarette (TOB), the electronic cigarette (eCIG), and the 
control (CON) conditions. 
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Figure 11. The results for haematocrit during the conventional cigarette (TOB), the 
electronic cigarette (eCIG), and the control (CON) conditions. 
 
 
Figure 12. The results for haemoglobin during the conventional cigarette (TOB), the 
electronic cigarette (eCIG), and the control (CON) conditions. 
 
 
The results for PaO2 are illustrated in figure 13. Friedman tests demonstrated a 
significant effect of time (i.e., pre, post, and 1h post) on PaO2 during all conditions (p<0.05). 
Post hoc Wilcoxon signed-rank tests revealed significant differences between pre-post 
(p=0.01) and between post-1h post (p=0.01) in the eCIG condition, as well as between pre-
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post (p=0.05) in the CON condition. Comparisons within the same time point revealed 
significant differences between TOB-eCIG and eCIG-CON at baseline, significant 
differences between TOB-eCIG and TOB-CON immediately after smoking, and a significant 
difference between TOB-eCIG 1 hour after smoking (p<0.05). 
  
Figure 13. The results for the partial pressure of oxygen in arterial blood (PaO2) during the 
conventional cigarette (TOB; in dark grey), the electronic cigarette (eCIG; in purple), and the 
control (CON; in light green) conditions. 
 
 
The results for PaCO2 are illustrated in figure 14. Friedman tests demonstrated a 
significant effect of time (i.e., pre, post, and 1h post) on PaO2 during the TOB condition 
(p<0.001). Post hoc Wilcoxon signed-rank tests revealed significant differences between pre-
post (p=0.001) and between post-1h post (p=0.001) in the TOB condition. Comparisons 
within the same time point revealed a significant difference between TOB-eCIG immediately 
after smoking, and significant differences between TOB-CON and eCIG-CON 1 hour after 
smoking (p<0.05). 
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Figure 14. The results for the partial pressure of carbon dioxide in arterial blood (PaCO2) 
during the conventional cigarette (TOB; in dark grey), the electronic cigarette (eCIG; in 




The results for the HCO3 are illustrated in figure 15. Friedman tests demonstrated a 
significant effect of time (i.e., pre, post, and 1h post) on HCO3 during the TOB condition 
(p=0.04). Post hoc Wilcoxon signed-rank tests revealed significant differences between pre-
post (p=0.001) and between post-1h post (p=0.001) in the TOB condition. Comparisons 
within the same time point revealed a significant difference between TOB-eCIG immediately 
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Figure 15. The results for the bicarbonate (HCO3) during the conventional cigarette (TOB; 




The results for pH are illustrated in figure 16. Friedman tests demonstrated no 
significant effect of time (i.e., pre, post, and 1h post) on pH in any of the conditions (p>0.05). 
Post hoc Wilcoxon comparisons within the same time point revealed significant differences 
between TOB-eCIG and between TOB-CON 1 hour after smoking (p<0.05). The results for 
oxygen saturation are illustrated in figure 17. Friedman tests demonstrated no significant 
effect of time (i.e., pre, post, and 1h post) on oxygen saturation in any of the conditions 
(p>0.05). Post hoc Wilcoxon comparisons within the same time point revealed a significant 
difference between TOB-eCIG at baseline, as well as significant differences between TOB-
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Figure 16. The results for pH during the conventional cigarette (TOB; in dark grey), the 




Figure 17. The results for the oxygen saturation during the conventional cigarette (TOB; in 
dark grey), the electronic cigarette (eCIG; in purple), and the control (CON; in light green) 
conditions. 
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Our aim in this study was to analyse the effects of conventional and e-cigarette consumption 
based on basic parameters such as spirometry and arterial blood gas analysis in COPD 
patients. The results from spirometry demonstrated that tobacco cigarettes generate a 
significant detrimental effect on lung function, evident by the reduction in FEV1 and 
Tiffneau Index. In contrast, e-cigarettes did not produce any statistically significant effects on 
spirometry results. In terms of arterial blood gas analysis, PaO2, PaCO2, HCO3, and oxygen 
saturation were unfavourably affected by tobacco cigarettes. In contrast, e-cigarettes did not 
produce any statistically significant effects on the results of arterial blood gases. 
Tobacco cigarette smoking undermines lung function, as serially shown in previous 
studies (Yates, Breen et al. 2001, Eisner, Wang et al. 2007, Metsios, Flouris et al. 2007, 
Flouris, Metsios et al. 2008, Flouris, Metsios et al. 2009, Flouris, Metsios et al. 2010). While 
chronic lung disease is normally a long-term process, we recently proposed that even brief 
exposures to air pollution stimulate mechanisms that contribute to its development (Flouris 
2009, Flouris, Metsios et al. 2009). Acute smoking causes localised lung inflammation, 
platelet aggregation, reduction of the number of eosinophils, suppression of repair 
mechanisms and impairment of the epithelial barrier (van der Vaart, Postma et al. 2004). All 
these mechanisms are heavily linked with the development and/or exacerbation of chronic 
lung disease. In the current study, this is of paramount importance since we were assessing 
COPD patients. In this light, e-cigarettes appeared to be less problematic for these patients, as 
compared to tobacco cigarettes. Of course, this does not mean that COPD patients should 
freely use e-cigarettes. As we only examined the acute effects of e-cigarette use, we cannot 
determine the long term effects of e-cigarette use based on the present data. Indeed, 
spirometry may fail to detect the initial and possibly mild effects from the short-term 
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inhalation of e-cigarette vapour on the respiratory system while repetitive use may provoke 
significant changes. In a recent study where spirometry results were normal, e-cigarette use 
was related to an increase on flow resistance detected by impulse osscilometry. Therefore, it 
is likely that these oncoming pathophysiological changes may not be represented in 
spirometric findings yet (Vardavas, Anagnostopoulos et al. 2011). Finally, it is important to 
note that the present results apply to the specific e-cigarette device and liquid tested and may 
not describe appropriately the acute usage of other devices and/or liquids. 
Based on the results of this study, it is concluded that acute e-cigarette smoking does 
not affect lung function (as assessed by spirometry) and arterial blood gases in COPD 
patients. In contrast, acute tobacco cigarette smoking undermines lung function and arterial 
blood gases in these patients. 
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Appendix B: Written consent form 
Έντυπο συναίνεσης δοκιμαζόμενου σε ερευνητική εργασία 
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Τίτλος Ερευνητικής Εργασίας: Βραχυπρόθεσμες επιπτώσεις ενεργητικού καπνίσματος 
συμβατικού και ηλεκτρονικού τσιγάρου στην πνευμονική λειτουργικότητα σε ασθενείς με 
διαγνωσμένη Χρόνια Αποφρακτική Πνευμονοπάθεια (ΧΑΠ). 
  
Επιστημονικός Υπεύθυνος-η: Αντρέας Φλουρής, Ερευνητής, ΤΕΦΑΑ, ΠΘ, Email: 
aflouris@cereteth.gr, τηλ: +30 2431 500 601, +30 2431 063 190 . 
 
Ερευνητής: Τσάρας Θεόδωρος (email: theomd@gmail.com, τηλ. 6945606100)  
 
Σκοπός της ερευνητικής εργασίας 
Σκοπός της μελέτης είναι η αξιολόγηση των βραχυπρόθεσμων επιπτώσεων στη  πνευμονική 
λειτουργία του καπνίσματος σε ασθενείς με διαγνωσμένη ΧΑΠ μετά από κάπνισμα 
συμβατικού τσιγάρου (ΣΤ) και ηλεκτρονικού τσιγάρου (ΗΤ). 
 
Διαδικασία  
Οι συμμετέχοντες θα αξιολογηθούν 3 φορές στη 3η Πνευμονολογική Κλινική του ΝΝΘΑ 
ΣΩΤΗΡΙΑ , με μεσοδιάστημα 7 ημερών, στις 09:00 πμ. Θα έχει προηγηθεί 12ωρη αποχή από 
κάπνισμα, είτε ενεργητικό είτε παθητικό. Την πρώτη φορά θα ληφθεί ιστορικό της 
καπνιστικής τους συνήθειας. 
Η ομάδα των καπνιστών τη μία ημέρα θα καπνίσει 2 ΣΤ της μάρκας τους μέσα σε 
διάστημα 30 λεπτών. Θα γίνει καταγραφή των ρουφηξιών που απαιτούνται για την 
ολοκλήρωση του καπνίσματος. Σε άλλη επίσκεψη θα καπνίσει ΗΤ, ακριβώς τον ίδιο αριθμό 
ρουφηξιών που απαιτήθηκαν για το κάπνισμα ΣΤ ο καθένας, μέσα σε 30 λεπτά. Σε άλλη 
επίσκεψη θα «καπνίσουν» ένα μη αναμμένο ΣΤ της επιλογής τους, πάλι τον ίδιο αριθμό 
ρουφηξιών σε 30 λεπτά (κατάσταση ελέγχου). Θα πραγματοποιηθούν κλινικές και 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:04:04 EET - 137.108.70.7
53 
 
εργαστηριακές μετρήσεις αμέσως πριν το κάπνισμα, αμέσως μετά τη λήξη του καπνίσματος, 
και 1 ώρα μετά τη λήξη του καπνίσματος. 
 
Κίνδυνοι και ενοχλήσεις 
Το δείγμα αίματος θα ληφθεί από τη βραχίονιο φλέβα. Δεν υπάρχει κανένας κίνδυνος 
τραυματισμού κατά τη διάρκεια των δοκιμασιών. Παρ’ όλα αυτά υπάρχει πρόβλεψη πρώτων 
βοηθειών και εκπαιδευμένο προσωπικό για κάθε ενδεχόμενο. 
 
Προσδοκώμενες ωφέλειες 
Με την συμμετοχή σας θα λάβετε πολλές πληροφορίες για το λειτουργικό σας προφίλ. Η 
διερεύνηση των επιδράσεων του καπνίσματος με ΗΤ ίσως αποτελέσει τη βάση  για την 
χρήση του ως συμπληρωματικό μέσο διακοπής του καπνίσματος προς όφελος των 
εξαρτημένων ατόμων αλλά και του κοινωνικού συνόλου. 
 
Δημοσίευση δεδομένων – αποτελεσμάτων 
Η συμμετοχή σας στην έρευνα συνεπάγεται ότι συμφωνείτε με την μελλοντική δημοσίευση 
των αποτελεσμάτων της, με την προϋπόθεση ότι οι πληροφορίες θα είναι ανώνυμες και δε θα 
αποκαλυφθούν τα ονόματα των συμμετεχόντων. Τα δεδομένα που θα συγκεντρωθούν θα 





Μη διστάσετε να κάνετε ερωτήσεις γύρω από το σκοπό ή την διαδικασία της εργασίας. Αν 
έχετε οποιαδήποτε αμφιβολία ή ερώτηση ζητήστε μας να σας δώσουμε διευκρινίσεις. 
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Ελευθερία συναίνεσης  
Η συμμετοχή σας στην εργασία είναι εθελοντική. Είστε ελεύθερος-η να μην συναινέσετε ή 
να διακόψετε τη συμμετοχή σας όποτε το επιθυμείτε. 
 
Δήλωση συναίνεσης  
Διάβασα το έντυπο αυτό και κατανοώ τις διαδικασίες που θα ακολουθήσω. Συναινώ να 
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Appendix C: Υπεύθυνη δήλωση πνευματικών δικαιωμάτων 
 
Υπεύθυνη Δήλωση 
Ο κάτωθι υπογεγραμμένος ΤΣΑΡΑΣ ΘΕΟΔΩΡΟΣ, μεταπτυχιακός φοιτητής του τμήματος  
ΤΕΦΑΑ του προγράμματος ΑΣΚΗΣΗ ΚΑΙ ΥΓΕΙΑ δηλώνω υπεύθυνα ότι αποδέχομαι τους 
παρακάτω όρους που αφορούν  
(α) στα πνευματικά δικαιώματα της Μεταπτυχιακής Διπλωματικής Εργασίας (ΜΔΕ)/ 
Διδακτορικής διατριβής μου μου με τίτλο: Βραχυπρόθεσμες επιπτώσεις ενεργητικού 
καπνίσματος συμβατικού και ηλεκτρονικού τσιγάρου στην πνευμονική λειτουργικότητα σε 
ασθενείς με διαγνωσμένη Χρόνια Αποφρακτική Πνευμονοπάθεια (ΧΑΠ). 
 (β) στη διαχείριση των ερευνητικών δεδομένων που θα συλλέξω στην πορεία εκπόνησής 
της: 
1. Τα πνευματικά δικαιώματα του τόμου της μεταπτυχιακής ή διδακτορικής διατριβής που θα 
προκύψει  θα ανήκουν σε μένα. Θα ακολουθήσω τις οδηγίες συγγραφής, εκτύπωσης και 
κατάθεσης αντιτύπων της διατριβής στα ανάλογα αποθετήρια (σε έντυπη ή/και σε 
ηλεκτρονική μορφή).  
2. Η διαχείριση των δεδομένων της διατριβής ανήκει από κοινού σε εμένα και στον κύριο 
επιβλέποντα καθηγητή.  
3. Οποιαδήποτε επιστημονική δημοσίευση ή ανακοίνωση (αναρτημένη ή προφορική), ή 
αναφορά που προέρχεται από το υλικό/δεδομένα της εργασίας αυτής θα γίνεται με 
συγγραφείς εμένα τον ίδιο, τον κύριο επιβλέποντα ή/και άλλους ερευνητές (πχ μέλη της 
τριμελούς συμβουλευτικής επιτροπής, συνεργάτες κλπ), ανάλογα με τη συμβολή τους στην 
έρευνα και στη συγγραφή των ερευνητικών εργασιών.  
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4. Η σειρά των ονομάτων στις επιστημονικές δημοσιεύσεις ή επιστημονικές ανακοινώσεις θα 
αποφασίζεται από κοινού από εμένα και τον κύριο επιβλέποντα της εργασίας,  πριν αρχίσει η 
εκπόνησή της. Η απόφαση αυτή θα πιστοποιηθεί εγγράφως μεταξύ εμού και του κύριου 
επιβλέποντος. 
 
Τέλος, δηλώνω ότι γνωρίζω τους κανόνες περί δεοντολογίας και περί λογοκλοπής και 
πνευματικής ιδιοκτησίας και ότι θα τους τηρώ απαρέγκλιτα καθ’ όλη τη διάρκεια της 
φοίτησης και κάλυψης των εκπαιδευτικών υποχρεώσεων μου που προκύπτουν από το 
ΠΜΣ/τμήμα και καθ’ όλη τη διάρκεια των διαδικασιών δημοσίευσης που θα προκύψουν 
μετά την ολοκλήρωση των σπουδών μου. 
 
[- ημερομηνία –] 
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